Fig. 1 · Structure

Documents & Downloads

Z-FL-COCHO (LY3000328)

Cat. No. A13502 CAS 907559-59-5

Cathepsin S inhibitor

Z-FL-COCHO (LY3000328) is a novel Cathepsin S inhibitor.

In Stock

Publications for Z-FL-COCHO

4 publications citing this product

  1. Gil-Im Mun, .et al. , Biochim Biophys Acta Mol Basis Dis, 2024, Sep 25;1871(1):167523 PMID: 39332782
  2. Fu R, .et al. , Sci Rep, 2020, Jan 29;10(1):1455 PMID: 31996771
  3. Klinngam W, .et al. , Sci Rep, 2019, Jul 2;9(1):9559 PMID: 31267034
  4. Chen CY, .et al. , Clin Sci (Lond), 2018, Oct 29;132(20):2221-2239 PMID: 30287519

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Z-FL-COCHO hydrate inhibited recombinant human cathepsin S (CTSS). A form-comparison experiment reported an IC50 of 261.9 ± 59.3 nM for the Adooq hydrate and 172.5 ± 32.7 nM for Z-FL. At 20 µM in mouse spleen lysates, the hydrate produced less inhibition than Z-FL, demonstrating assay-context and form-dependent activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Z-FL-COCHO (LY3000328) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Z-FL-COCHO (LY3000328) from 2 published references. In vitro models include SV-40-transformed human corneal epithelial HCE-T cells.

Z-FL-COCHO (LY3000328) In Vitro Studies

In IFN-γ-stimulated human corneal epithelial HCE-T cells, Z-FL-COCHO reported as Adooq A13502 (1 µM during the final 2 hours of a 24-hour stimulation) reduced extracellular CX3CL1 and CTSS activity. Neither corresponding cell-lysate measurement changed significantly. The paper does not characterize the tested material’s hydration state. [2]

Form-specific inhibition of recombinant CTSS and spleen-lysate CTSS

Biochemical assay · Recombinant human CTSS and spleen lysates from 16-week-old male NOD mice [1]

The hydrate inhibited recombinant human CTSS, but showed less inhibition than Z-FL in spleen lysates at the same nominal concentration. The two assay contexts do not establish interchangeable tissue potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Recombinant human CTSS inhibition by the tested batchesIC50 Z-FL-hydrate: 261.9 ± 59.3 nM; Z-FL: 172.5 ± 32.7 nM[1]
CTSS inhibition in spleen lysates at 20 µMBetween-form comparison Less inhibition with Z-FL-hydrate than Z-FL; P = 0.0007; n = 4; mean ± SD[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response assay for recombinant CTSS; 20 µM of each form for spleen lysates
Method
Addition to enzyme or spleen-lysate activity assay
Co-treatment
Direct comparison of hydrate and Z-FL; no therapeutic combination
Reported limits
Assay incubation time, panel-C replicate count/dispersion definition and assay solvent are not specified in the acquired relevant text. The 12.5 nM enzyme concentration stated for collected HPLC fractions in panel B is not transferred to panel C.
Methods and source locations

Compound reported in the paper: Z-FL-COCHO hydrate; Compound label in the paper: Z-FL-hydrate (Adooq Bioscience); comparator Z-FL (Millipore)

Applies to the peptide hydrate tested; comparator results are labeled separately. No equivalence to nonpeptidic LY3000328 or present Adooq lots is inferred.

Figure 8A–D and caption; Results, Identification of Z-FL-hydrate effective dose; Methods, Reagents and CTSS activity assays

Recombinant human CTSS inhibition by the tested batches: Fluorometric CTSS activity assay. The caption does not define the ± statistic or replicate count specifically for panel C. — Figure 8C and caption; Methods, CTSS activity assays

CTSS inhibition in spleen lysates at 20 µM: CTSS activity assay; two-tailed unpaired Student’s t-test. No inhibition percentages estimated from the plot. — Figure 8D and caption; Methods, CTSS activity assays

A13502 reduces extracellular CX3CL1 and CTSS activity in IFN-γ-treated HCE-T cells

Cell-based study · SV-40-transformed human corneal epithelial HCE-T cells (RIKEN RCB2280) [2]

During IFN-γ stimulation, Z-FL reduced CX3CL1 in culture medium and extracellular CTSS activity, with no significant change in the corresponding cell-lysate measurements. This supports an extracellular CTSS-associated shedding mechanism in this cell model; it does not establish a universal anti-inflammatory effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CX3CL1 in culture medium and cell lysateELISA comparison Medium decreased with Z-FL: p = 0.0232; cell lysate not significantly affected; N = 3 experimental repeats on different days; mean ± SD[2]
CTSS activity in culture medium and cell lysateFluorometric activity comparison Medium activity reduced with Z-FL: p = 0.0048; cell lysate unchanged; N = 3 experimental repeats on different days; mean ± SD[2]

Literature-Reported Treatment Conditions

Treatment concentration
Z-FL 1 µM
Exposure duration
Z-FL during the final 2 hours of a 24-hour IFN-γ exposure
Method
Cell culture exposure
Vehicle
Z-FL solvent not specified in the acquired relevant text
Co-treatment
Recombinant human IFN-γ, 1 µg/mL, for 24 hours; matched IFN-γ exposure without Z-FL as comparator
Reported limits
Hydration state, CAS identifier and lot-level analytical characterization are not specified. No extra recombinant CTSS is stated for the adopted D/E inhibitor comparison; the active/heat-inactivated enzyme experiments are separate controls in A–C.
Methods and source locations

Compound reported in the paper: Z-FL-COCHO; Compound label in the paper: Z-FL, Adooq Bioscience #A13502

Applies to the material reported as A13502 under the stated cell conditions; hydration-state-specific potency is not inferred from this experiment.

Figure 6D,E and caption; Results, Extracellular CTSS enhances CX3CL1 shedding in HCE-T cells; Methods, Reagents, HCE-T culture/treatments, ELISA and Statistics

CX3CL1 in culture medium and cell lysate: Human CX3CL1/fractalkine Quantikine ELISA; content normalized to total protein. Comparator: IFN-γ-exposed cells without Z-FL. — Figure 6D and caption; Methods, ELISA measurements of CX3CL1

CTSS activity in culture medium and cell lysate: Fluorometric CTSS activity readout, plotted as RFU/µg total protein in Figure 6E; comparator without Z-FL. No exact values inferred from bars. — Figure 6E and caption; Methods, Reagents (activity kit listed)

Z-FL-COCHO (LY3000328) In Vivo Studies

In male NOD mice, Z-FL-COCHO hydrate (15 mg/kg intraperitoneally every other day for 2 weeks) reduced lacrimal-gland and spleen CTSS activity, reduced gland lymphocytic infiltration and increased stimulated tears versus vehicle. Tear CTSS inhibition and corneal-staining improvement were not significant. Basal tears increased within the treated group; that paired comparison does not establish a treatment-versus-vehicle change. [1]

Systemic Z-FL hydrate in male NOD mice with autoimmune dacryoadenitis

Animal study · 14–15-week-old male NOD/ShiLtJ mice; established autoimmune dacryoadenitis model [1]

Compared with vehicle, the hydrate reduced CTSS activity in lacrimal gland and spleen, reduced gland lymphocytic infiltration and increased stimulated tears. Tear CTSS activity and corneal staining did not improve significantly. Basal tears increased within the treated group; the reported paired result is not a treatment-versus-vehicle change analysis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CTSS activity in tears, lacrimal gland and spleenFluorometric activity comparison LG: P = 0.04 (vehicle n = 8, drug n = 9); spleen: P = 0.03 (vehicle n = 8, drug n = 9); tear decrease not significant (vehicle n = 7, drug n = 9)[1]
Percentage of lacrimal gland area occupied by lymphocytic infiltratesHistological comparison Reduced with hydrate versus vehicle; P = 0.04; n = 13 mice/group; mean ± SD[1]
Stimulated tear secretion and basal tear secretionBetween-group and within-group comparisons Stimulated tears: increased versus vehicle, P = 0.011 (vehicle n = 7, drug n = 9). Basal tears: increased from pretreatment within drug group, P = 0.03 (n = 13/group); mean ± SD[1]
Corneal fluorescein staining scorePaired comparison No significant improvement after 2 weeks; n = 13 mice/group; mean ± SD[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every other day
Treatment course
2 weeks
Vehicle
10% DMSO + 40% PEG 300 + 50% sterile PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Z-FL-hydrate
15 mg/kg body weight
Matched vehicle groupCompared with vehicle, the hydrate reduced CTSS activity in lacrimal gland and spleen, reduced gland lymphocytic infiltration and increased stimulated tears. Tear CTSS activity and corneal staining did not improve significantly. Basal tears increased within the treated group; the reported paired result is not a treatment-versus-vehicle change analysis.[1]
Z-FL-hydrate
Model: 14–15-week-old male NOD/ShiLtJ mice; established autoimmune dacryoadenitis model
Reported limits: Started n = 15; analyzed cohort n = 13 after two diabetes exclusions. Endpoint-specific n are in measurements; pharmacokinetics not established.
Methods and source locations

Compound reported in the paper: Z-FL-COCHO hydrate; Compound label in the paper: Z-FL-hydrate (Adooq Bioscience)

Form-specific preclinical findings in male NOD mice; no human efficacy, clinical dosing, general safety or current-lot validation claim.

Figure 9A–E and caption; Results, Intraperitoneal Z-FL-hydrate significantly reduces CTSS activity…; Methods, Mice, preparation, i.p. administration, histology, tear collection and Statistics

CTSS activity in tears, lacrimal gland and spleen: Mean ± SD; two-tailed unpaired Student’s t-test. Activity normalized to total protein. — Figure 9A and caption; hydrate-cohort Results; Methods, CTSS activity assays

Percentage of lacrimal gland area occupied by lymphocytic infiltrates: Histological quantification; two-tailed unpaired Student’s t-test. — Figure 9B and caption; Methods, LG histology

Stimulated tear secretion and basal tear secretion: Stimulated tear collection: unpaired t-test. Basal tear thread test: paired pretreatment versus 2-week comparison. — Figure 9C,D and caption; Methods, Tear collection and Statistics

Corneal fluorescein staining score: Corneal staining assessed before and after treatment; paired Student’s t-test in figure caption. — Figure 9E and caption; hydrate-cohort Results

Z-FL-hydrate · Figure 9A–E; Methods, Administration of Z-FL and Z-FL-hydrate by i.p. injection

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 907559-59-5
Applications Cathepsin S inhibitor
Formula C24H30N2O6
Molecular Weight 442.5
Synonyms Cathepsin S inhibitor; LY3000328
SMILES
CC(C)C[C@@H](C(=O)C(O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Z-FL-COCHO (LY3000328) Research References

  1. [1] Wannita Klinngam, Srikanth R. Janga, Changrim Lee, et al. Inhibition of Cathepsin S Reduces Lacrimal Gland Inflammation and Increases Tear Flow in a Mouse Model of Sjögren’s Syndrome Scientific Reports (2019). PMID: 31267034 DOI: 10.1038/s41598-019-45966-7 Source material
  2. [2] Runzhong Fu, Hao Guo, Srikanth Janga, et al. Cathepsin S activation contributes to elevated CX3CL1 (fractalkine) levels in tears of a Sjögren’s syndrome murine model Scientific Reports (2020). PMID: 31996771 DOI: 10.1038/s41598-020-58337-4 Source material

Publications

4 publications citing this product

  1. Gil-Im Mun, .et al. , Biochim Biophys Acta Mol Basis Dis, 2024, Sep 25;1871(1):167523 PMID: 39332782
  2. Fu R, .et al. , Sci Rep, 2020, Jan 29;10(1):1455 PMID: 31996771
  3. Klinngam W, .et al. , Sci Rep, 2019, Jul 2;9(1):9559 PMID: 31267034
  4. Chen CY, .et al. , Clin Sci (Lond), 2018, Oct 29;132(20):2221-2239 PMID: 30287519

Added to your cart

View Cart Checkout
Loading...